Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOMEORAD: Homeopathic Radium bromatum for prevention and treatment of radiodermatitis in breast cancer radiotherapy
2018-002406-32Phase 3Completed
- Sponsor
- Institut de Cancérologie Lucien Neuwirth
- Start
- Oct 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of radium bromide in radiodermatitis and breast cancer (2 arms), sponsored by Institut de Cancérologie Lucien Neuwirth. Primary endpoint: Incidence of grade ≥2 radiodermatitis. Started Oct 2018; status: completed.
02
Drugs
radium bromide
03
Conditions
radiodermatitisbreast cancer
Beyond the preview
Go deeper on 2018-002406-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002406-32.